Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity

BMC Cancer

Xia Yang²  Hai-jian Sun²  Zhi-rong Li²  Hao Zhang²  Wei-jun Yang¹  Bing Ni²  Yu-zhang Wu² 

[1] Department of General Surgery, First People’s Hospital of Guiyang, Guiyang 550002, PR China

[2] Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Shapingba District, Chongqing 400038, PR China

关键词: Clinicopathological characteristics;    VEGF;    Gastric cancer;    Von Willebrand factor;   

Others  :  1134519
DOI  :  10.1186/s12885-015-1083-6

 received in 2014-09-10, accepted in 2015-02-12,  发布年份 2015

【 摘 要 】

Background

von Willebrand factor (vWF) is a potent regulator of angiogenesis, tumor growth, and metastasis. Yet, the expression pattern of vWF in human gastric cancer (GC) tissues and its relation to clinicopathological features of these cases remains unknown.

Methods

Tumor and 5-cm adjacent non-tumoral parenchyma specimens were collected from 99 patients with GC (early stages I/II and late stages III/IV), and normal specimens were collected from 32 healthy controls (reference group). Plasma vWF antigen (vWF:Ag) and vWF activity were assessed by ELISA. The role of vascular endothelial growth factor (VEGF) in differential vWF expression was investigated using cultured human umbilical vein endothelial cells (HUVECs). vWF and VEGF protein and mRNA expression levels were investigated by qRT-PCR, western blotting and immunohistochemistry (IHC) respectively. The correlation of IHC-detected vWF expression with patient clinicopathological characteristics was analyzed.

Results

Compared to the reference group, the patients with late GC showed significantly higher levels of vWF:Ag (72% (21-115) vs. 101% (40-136)) and vWF activity (62% (20-112) vs. 117% (33-169)) (both P < 0.001). The GC tumor tissues also showed higher vWF mRNA and protein levels than the adjacent non-tumoral parenchyma. Patients at late GC stage had significantly higher median number of vWF-positive cells than patients at early GC stage (P < 0.05). VEGF induced vWF mRNA and protein expression in HUVECs in dose- and time-dependent manners. Patients with late GC stage also had significantly higher serum VEGF than patients at early GC stage (23 ± 26 vs. 10 ± 12 pg/mL, P < 0.01). Most of the undifferentiated GC tumor tissues at late disease stage exhibited strong VEGF and VEGFR2 protein staining, which co-localized with the vWF protein staining pattern.

Conclusions

GC-related plasma vWF:Ag and vWF activity levels become substantially elevated in the late stage of disease. The higher mRNA and protein expression of vWF in GC tumor stroma may be regulated by the VEGF-VEGFR2 signaling pathway in vitro and may contribute to GC progression in vivo.

【 授权许可】

   
2015 Yang et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Dikken JL, van de Velde CJ, Coit DG, Shah MA, Verheij M, Cats A: Treatment of resectable gastric cancer. Therap Adv Gastroenterol 2012, 5(1):49-69.
• [2]Yang X, Qian F, He HY, Liu KJ, Lan YZ, Ni B, et al.: Effect of thymosin alpha-1 on subpopulations of Th1, Th2, Th17, and regulatory T cells (Tregs) in vitro. Braz J Med Biol Res 2012, 45(1):25-32.
• [3]Huang TC, Yeh KH, Cheng AL, Hsu CH: Weekly 24-hour infusional 5-fluorouracil as initial treatment for advanced gastric cancer with acute disseminated intravascular coagulation. Anticancer Res 2008, 28(2B):1293-1297.
• [4]Lesesne JB, Rothschild N, Erickson B, Korec S, Sisk R, Keller J, et al.: Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989, 7(6):781-789.
• [5]Kakeji Y, Hashizume M, Kitano S, Hasuo K, Sugimachi K: Successful treatment of Budd-Chiari syndrome with early gastric cancer. Int Surg 1991, 76(1):55-57.
• [6]Wojtukiewicz MZ, Sierko E, Zacharski LR, Zimnoch L, Kudryk B, Kisiel W: Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer. Semin Thromb Hemost 2003, 29(3):291-300.
• [7]van den Berg YW, Osanto S, Reitsma PH, Versteeg HH: The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012, 119(4):924-932.
• [8]Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, et al.: Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 2004, 109(11):1343-1348.
• [9]Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gomez Garcia EB, et al.: High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. Stroke 2006, 37(11):2672-2677.
• [10]Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O: Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study. J Neurol Neurosurg Psychiatry 2007, 78(7):699-701.
• [11]Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M, et al.: Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011, 57(25):2496-2504.
• [12]Khaleghi M, Singletary LA, Kondragunta V, Bailey KR, Turner ST, Mosley TH Jr, et al.: Haemostatic markers are associated with measures of vascular disease in adults with hypertension. J Hum Hypertens 2009, 23(8):530-537.
• [13]Chen J, Hobbs WE, Le J, Lenting PJ, de Groot PG, Lopez JA: The rate of hemolysis in sickle cell disease correlates with the quantity of active von Willebrand factor in the plasma. Blood 2011, 117(13):3680-3683.
• [14]Luo GP, Ni B, Yang X, Wu YZ: von Willebrand factor: more than a regulator of hemostasis and thrombosis. Acta Haematol 2012, 128(3):158-169.
• [15]Terraube V, Pendu R, Baruch D, Gebbink MF, Meyer D, Lenting PJ, et al.: Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost 2006, 4(3):519-526.
• [16]Mochizuki S, Soejima K, Shimoda M, Abe H, Sasaki A, Okano HJ, et al.: Effect of ADAM28 on carcinoma cell metastasis by cleavage of von Willebrand factor. J Natl Cancer Inst 2012, 104(12):906-922.
• [17]Starke RD, Ferraro F, Paschalaki KE, Dryden NH, McKinnon TA, Sutton RE, et al.: Endothelial von Willebrand factor regulates angiogenesis. Blood 2011, 117(3):1071-1080.
• [18]Lackner C, Jukic Z, Tsybrovskyy O, Jatzko G, Wette V, Hoefler G, et al.: Prognostic relevance of tumour-associated macrophages and von Willebrand factor-positive microvessels in colorectal cancer. Virchows Arch 2004, 445(2):160-167.
• [19]Mahzouni P, Mohammadizadeh F, Mougouei K, Moghaddam NA, Chehrei A, Mesbah A: Determining the relationship between "microvessel density" and different grades of astrocytoma based on immunohistochemistry for "factor VIII-related antigen" (von Willebrand factor) expression in tumor microvessels. Indian J Pathol Microbiol 2010, 53(4):605-610.
• [20]Wei ZF, Tong B, Xia YF, Lu Q, Chou GX, Wang ZT, et al.: Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-kappaB/c-Fos/NFATc1 Pathways. PLoS One 2013, 8(3):e59171.
• [21]Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, et al.: Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005, 11(14):2166-2170.
• [22]Martini F, Ferroni P, Guadagni F, Basili S, Spila A, D'Alessandro R, et al.: Plasma von Willebrand factor antigen levels in non-small cell lung cancer patients. Anticancer Res 2005, 25(1B):403-407.
• [23]Toth B, Nieuwland R, Liebhardt S, Ditsch N, Steinig K, Stieber P, et al.: Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers. Anticancer Res 2008, 28(2A):1107-1112.
• [24]Schellerer VS, Mueller-Bergh L, Merkel S, Zimmermann R, Weiss D, Schlabrakowski A, et al.: The clinical value of von Willebrand factor in colorectal carcinomas. Am J Transl Res 2011, 3(5):445-453.
• [25]Matsuyama T, Uemura M, Ishikawa M, Matsumoto M, Ishizashi H, Kato S, et al.: Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2007, 31(1):S 27-35.
• [26]Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, et al.: Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006, 44(1):53-61.
• [27]Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T: An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. Hepatology 2013, 58(2):752-761.
• [28]Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY: Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002, 106(15):1962-1967.
• [29]Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY: Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation. Circulation 2003, 107(25):3141-3145.
• [30]Zanetta L, Marcus SG, Vasile J, Dobryansky M, Cohen H, Eng K, et al.: Expression of Von Willebrand factor, an endothelial cell marker, is up-regulated by angiogenesis factors: a potential method for objective assessment of tumor angiogenesis. Int J Cancer 2000, 85(2):281-288.
• [31]Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al.: IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71(2):424-434.
• [32]Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF: A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci 2006, 103(39):14519-14524.
• [33]Koh SC, Khalil R, Lim FK, Ilancheran A, Choolani M: The association between fibrinogen, von Willebrand Factor, antithrombin III, and D-dimer levels and survival outcome by 36 months from ovarian cancer. Clin Appl Thromb Hemost 2006, 12(1):3-8.
• [34]Xiong Y, Huo Y, Chen C, Zeng H, Lu X, Wei C, et al.: Vascular endothelial growth factor (VEGF) receptor-2 tyrosine 1175 signaling controls VEGF-induced von Willebrand factor release from endothelial cells via phospholipase C-gamma 1- and protein kinase A-dependent pathways. J Biol Chem 2009, 284(35):23217-23224.
• [35]Ripoll GV, Alonso DF: Implication of von Willebrand factor as a regulator of tumor cell metastasis: potential perioperative use of desmopressin and novel peptide analogs. Acta Haematol 2013, 129(4):223-224.